Cancer drug sales are slowing down in the U.S., Reuters reported Monday.
A brain cancer vaccine from Immunocellular Therapeutics has yielded positive results in a small Phase I clinical trial.
Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.